Research on the Selection of Vaccine Seeds with the HI Method Approach to Improve the Quality of Avian Influenza Vaccines

Nining Nuraeni\textsuperscript{1}, Entang Bustanudin\textsuperscript{2}, Dine Resti Susanti\textsuperscript{2}, Intan Nur Rachmanita\textsuperscript{3}, Desri Wijayanti\textsuperscript{3}, Fedik A. Rantam\textsuperscript{4}

\textsuperscript{1}Masters in vaccinology and immunotherapeutics, Faculty of Veterinary Medicine, UNAIR
\textsuperscript{2}RnD at PT Caprifarmindo Laboratories
\textsuperscript{3}QC staff of PT Caprifarmindo Laboratories
\textsuperscript{4}Lecturer in the Master’s Program in Vaccinology and Immunotherapeutics, FKH UNAIR

*Corresponding Author: Nining Nuraeni
E-mail: niningnuraeni.av35@gmail.com

Abstract

AI virus is a virus that is easily mutated because it has a single chain of RNA that is unstable, so many strains appear in the field. Currently in the field (in Indonesia), it is known that there are 2 vaccine strains that dominate, namely AI H5N1 Clade 2.1.3 and AI H5N1 Clade 2.3.2. The incompatibility of seed viruses used as vaccine seeds will hinder the eradication of AI disease in Indonesia. Therefore, it is necessary to select and develop seed viruses as new vaccine seed candidates to obtain vaccines with high quality, safe, homologous, and able to cover viruses in the field. Development activities carried out by researchers aim to obtain vaccine seeds that are able to protect against AI clade 2.1.3 virus and AI clade 2.3.2. The vaccine candidates to be developed are several vaccine candidates derived from the isolation of chicken organs from AI outbreak areas in several areas on the island of Java which include West Java, Central Java and East Java which were found around 2010 to 2013. These isolates are processed and then propagated on the SPF TAB and passaged until a high viral titter is obtained. After that, identification, pathogenicity, immunogenicity and protective tests were carried out. From the results of this development, AI C-8 and C-11 virus seeds were obtained which are able to protect against both AI Clade 2.1.3 and AI Clade 2.3.2.

Introduction

Since 2003 until now, bird flu outbreaks (Avian Influenza) have caused very high poultry mortality and economic losses in various countries in Asia such as Vietnam, Thailand, China, Japan, South Korea, Laos and Indonesia (Ernawati, 2011; Yadav, 2022). In addition to causing high economic losses, the highly pathogenic Avian Influenza virus (HPAI/High Pathogen Avian Influenza) cause panic because it can pass through a Barrier between poultry and humans, which means that it can be contagious and deadly to humans and become a pandemic threat (Ernawati, 2011; Sims & Brown, 2016).

Many government efforts have been made to overcome the outbreak of bird flu, including the destruction of infected birds within a certain radius (stamping out/culling), biosecurity and vaccination. Vaccination is one of the government’s programs to prevent bird flu outbreaks in Indonesia (Behrens et al., 2006; Indriani et al., 2011; Swayne, 2012).

Various AI vaccine preparations for poultry have been widely produced by several government agencies and private companies in Indonesia (Ernawati, 2011; Fournié et al., 2012). A common
preparation for AI vaccines in the form of emulsions with oil adjuvants. The vaccine can protect poultry from clinical symptoms and death, but does not suppress viral excretion. This raises doubts in preventing transmission of the virus between animals and increases the risk of new outbreaks and becoming a threat to public health (Bett et al., 2015; Ernawati, 2011).

Another problem in vaccination strategy is the determination of seed virus used as raw material in vaccine manufacturing (Venkataraman et al., 2021; Webster et al., 1992). AI vaccines are RNA viruses that are genetically easy to mutate, and quickly change their antigen structure so determining vaccine seeds that are guaranteed to be safe, effective, and genetically stable and antigenically homologous is a problem that is not easy (Ernawati, 2011; Smith et al., 2006; Charlesworth et al., 202).

Therefore, research was conducted on the selection of vaccine seeds as raw material seeds in making vaccines with the HI method to improve the quality of AI vaccines by making single vaccines which were then challenged with various kinds of local AI strain antigens owned by PT. Caprifarmando Laboratories.

Methods

Virus isolation

Isolation of samples came from sick chickens in West Java, Central Java and East Java. AI virus sampling techniques were carried out with organ scouring techniques. The organ scouring technique is done by taking some pieces of organs such as respiratory organs (trachea and lungs), digestive organs (proventriculus, intestines), lymphoid organs (liver, spleen, bursa Fabricius), and brain. These organs are washed using PBS that has been added to antibiotics and crushed to make 10% suspension. Furthermore, the 10% suspension is carried out freeze-thawing As many as 3 times, then centrifuge at 6000 rpm for 10-15 minutes. The supernatant is taken and then inoculated on 3 grains of TAB (embryonated chicken eggs) which are SPF (Specific Pathogen Free) aged 9 - 11 days. Then incubated at a temperature of 37°C for 5 days. This TAB is observed to develop every 2 hours using candling. If there is a TAB whose embryo dies, it is put in the refrigerator temperature 4°C for distilling. Allantois fluid from TAB that has been in chilling was harvested for Rapid HA testing (Rapid Test) by reacting 1 part allantois liquid with 1 part RBC 10%. If there is an isolate sample that is positive for agglutination, a rapid-blocking agglutination test is carried out using AI serum to find out whether the isolate sample is an AI virus. If the blocking results show no agglutination, the isolate sample is positive for the AI virus. Positive samples are stored within -86°C. Furthermore, identification tests were carried out, including biomolecular tests, identification tests by method Cross micro technical HA reactions, virus content tests, pathogenicity tests on SPF embryonic chicken eggs, pathogenicity tests in chickens, and then evaluated immunogenicity and protectivity as the final product of the vaccine.

Biomolecular Test

Biomolecular identification in this study was only carried out on isolate C-11, because isolate C-8 and other isolates had been carried out in previous research.

Polymerase Chain Reaction (PCR)

Virus testing using PCR is carried out by isolating DNA/RNA using Purelink RNA/DNA Kit (Invitrogen, 12280050). The procedure applied is adapted from the protocol issued by the manufacturer by the spin column method. The results of RNA/DNA isolation are identified and stored at -20°C for DNA and -86°C for RNA.

The RNA-isolated samples obtained were then converted to cDNA form using the Reverse Transcriptase enzyme in the Polymerase Chain Reaction (PCR) process. After that, samples were amplified using H5-155f: 5'-ACACATGCYCARGACATACT-3' and H5-699r: 5'-
CTYTGRTTYAGTGTGTATGT-3' primers with a target length of about 545 bp. PCR results are then detected using electrophoresis techniques.

**Sequencing**

PCR products are detected with amplification lengths according to the primary target, and then purification and nucleotide sequencing are carried out using Genetic Analyzer 3500 (Applied Biosystems). DNA sequences were analysed using Mega 5 Software.

**Micro technical HA Test**

The HA test is used to determine the antigen titter. The HA test procedure is microplate holes from A1 to A12 filled with 25μl PBS (Phosphate Buffer Saline) depending on the amount of shampoo. Samples are inserted as much as 25μl in holes A1, B1, and so on depending on the number of samples. Next, a serial dilution is carried out from holes A1 to A11, then remove 25μl from hole A11, because hole A12 is the control, and so on for the next sample. 1% RBC is inserted as much as 25μl from hole A1 to A12. Then incubated at room temperature for 30–45 minutes. The HA titter is read at the last hole that still causes agglutination.

**Test Virus Content**

A virus content test is a test to determine the dose of virus that can infect 50 percent of TAB expressed with EID<sub>50</sub> units (Effective Infectious dose). Virus content test procedure by providing 20 SPF TAB items. Then 8 threaded test tubes that have been filled with PBS of 9ml each. Furthermore, the sample (harvested from allantois liquid) is inserted in the first tube as much as 1ml, homogenize, then 1ml is taken from the first tube and inserted into the second tube and so on 10x dilution is done. Furthermore, in 5 grains of SPF TAB with dilutions of -8, -7, -6, -5 respectively were injected as much as 0.1ml in each dilution. Further incubated for 5 days on an incubator 37°C. And observations were made every day and his death was recorded. TABs that are dead in chilling. The assessment is carried out at the end of the observation, using the formula from Method calculation “Spearman – Karber” based on log 10 EID<sub>50</sub>.

\[
\text{EID}_{50} = X + \frac{d \sum r}{n} \frac{1}{2} d
\]

**Description:**

\[X = \log \text{of depletion that still gives positive results}\]

\[\Sigma r = \text{number of negatives}\]

\[n = \text{number of eggs used in each dilution}\]

\[d = \log \text{of dilution factor}\]

\[(\log 10 = 1)\]

**Pathogenicity in SPF eggs**

The eggs used are embryonated SPF eggs with an incubation period of 10–11 days as many as 5 eggs. Each egg was inoculated with 0.1 ml virus containing 1000 virus particles, then incubated at 37°C and observed (candling) every 2 hours. Record the time of death and chilling first before the rapid agglutination test. A malignant virus is the fastest infecting embryo characterized by embryonic death and agglutination.

**Pathogenicity in SPF Chickens**

Inoculate the virus as much as 10<sup>7</sup> in chickens aged 3–4 weeks, observe every day, and note the onset of clinical symptoms (start to illness) and death. In dead chickens, an autopsy is performed and changes in anatomical pathology (PA) are seen, the malignant virus is the virus
that most quickly infects chickens characterized by clinical symptoms (illness) which is usually followed by chicken death and changes in PA in organs.

**Inactive bulk product manufacturing**

Inactivated bulk products are raw materials in the manufacture of vaccines. The procedure is to first dilute the virus titter obtained from the virus content test to $10^3$ per dose. Furthermore, 0.1 ml was injected in 30 grains of SPF TAB. Then incubated in an incubator at 37°C for 5 days. Chickens that die in chilling. After 5 days of harvesting allantois liquid from each TAB. The harvest of allantois liquid is centrifuge 2500 for 15 minutes. The supernatant is taken, then the antigen must first be inactivated with 37% Formaldehyde with a final concentration of 0.2%. Then incubate at room temperature overnight while turning.

**Immunogenicity and Protectivity**

This test was carried out using 3 batches of vaccines containing AI Capri-8 and AI Capri-11 antigens injected with 1 dose/head in SPF chickens aged 4 weeks. Each batch required 30 vaccination groups and 30 control groups (unvaccinated) Three weeks after vaccination, blood was taken and serum, for titter (HI) testing, and then all chickens were inoculated with Al challenge virus with a content of $10^6$ ELD$_{50}$. Observation 14 days after virus inoculation challenge.

**Vaccine Manufacturing**

The vaccine is made in an emulsion preparation using an oil adjuvant in the ratio of 30% antigen and 70% adjuvant.

**Antiserum Manufacturing**

The vaccine is injected into 10 4-week-old SPF chickens as much as 0.3 ml per dose. Three weeks later the chicken had its blood drawn to separate its serum. The obtained serum is inactivated on a water bath at 56°C for 30 minutes, for further HI testing (Haemagglutination Inhibition) to determine the titter of antibodies elicited by the vaccine.

**Result and Discussion**

**Biomolecular Test (of AI H5N1 Isolate C-11)**

**Polymerase Chain Reaction (PCR)**

*Figure 1. The electrophoresis yield of agarose gel 2%. M: marker 500 bp – 1 kb; 11: AI H5N1 C 11*
The PCR product in the sample has been successfully amplified with a length of approximately 544 bp, according to the primary target used. This is shown in the results of electrophoresis on 2% agarose gel (Figure 1).

**Sequencing**

**Data sequencing virus AI H5N1 C-11 (A/CK/C-11/Jatim/2010)**

CTGGAAAGGACACAACGGGAAGCTGCATCTAGATGGAGTGAAGCCTCTATT
TTAAAAGATTGCAGTGTAGCTGGATGGCTCCTCGGGAACCCAATGTGTGAC
AATTCATCAAAGTACCAGACATTCTGGAGATTGCAGTGTAGCTGGATGGCT
TAGCATGAAGCATCATCAGAGTGAAGCTAGCATGCCCATACCTGGGAAGTCC
CTCTTTTTTCTAGAATGTTGATGCTATATCAAACACGATCAGTACCCCAAC
TAAGAAGAAGCTACATAATACCAAGACATCTTTTGTATGACTGAGGGAGA
TTACATCATCTAATAATGAGGGCAGAGACAAATGCTATATATAACAAAA
CCACAAACTGGGACAT

The results of nucleotide sequence alignment of AI seed C-11 gene H5 using BLAST NCBI (table 1.2) showed a 99% level of proximity (identity) with Influenza A virus (A/chicken/Indonesia/SmiWN18/2009(H5N1)) accession no. JF302895.1 and Influenza A virus (A/chicken/West Java/M35/2010(H5N1)) accession no. KR078232.1 originating from West Java.

Based on the phylogenetic tree by including several other vaccine seeds, AI Capri -11 has proximity to AI C-8 seeds and several West Java AI seeds (Table 1.1).

**Table 1. Alignment Results Using NCBI BLAST**

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Description</th>
<th>Country</th>
<th>Identity</th>
<th>Accession</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI-C-11</td>
<td>Influenza A virus (A/chicken/Indonesia/SmiWN18/2009(H5N1)) segment 4hemagglutinin (HA) gene, partial cds</td>
<td>Indonesia</td>
<td>99%</td>
<td>JF302895.1</td>
</tr>
<tr>
<td></td>
<td>Influenza A virus (A/chicken/West Java/M35/2010(H5N1)) segment 4 hemagglutinin (HA) gene, partial cds</td>
<td>West Java, Indonesia</td>
<td>99%</td>
<td>KR078232.1</td>
</tr>
<tr>
<td></td>
<td>Influenza A virus (A/chicken/Indonesia/D10014/2010(H5N1)) HA gene for hemagglutinin, complete cds</td>
<td>Indonesia</td>
<td>99%</td>
<td>AB621353.1</td>
</tr>
</tbody>
</table>

**Phylogenetic Tree Using Mega 5 Software**

The evolutionary history was inferred using the Neighbor-Joining method. The optimal tree with the sum of branch length = 0.93985840 is shown. The evolutionary distances were computed using the Maximum Composite Likelihood method and are in the units of the number of base substitutions per site. The analysis involved 25 nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 216 positions in the final dataset. Evolutionary analyses were conducted in MEGA5.
Micro technical HA Test

Table 2. Result of Rapid Blocking Agglutination Test

<table>
<thead>
<tr>
<th>Sample</th>
<th>Hyperimmun Antisera</th>
<th>ND</th>
<th>EDS</th>
<th>AI PWT</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI C-8 Antigen</td>
<td>Agglutination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AI C-11 Antigen</td>
<td>Agglutination</td>
<td></td>
<td></td>
<td>Negative</td>
</tr>
</tbody>
</table>

Source: RnD Report, 2014

Pathogenesis

Pathogenicity in SPF eggs

Table 3. The Mean Death Time and Anatomical Pathology Appearance of The Embryos

<table>
<thead>
<tr>
<th>Sample</th>
<th>Number of Particles</th>
<th>Mean Death Time</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI C-8</td>
<td>$10^3$</td>
<td>24-26 hours</td>
<td>Haemorrhage throughout the embryo's body</td>
</tr>
<tr>
<td>AI C-11</td>
<td>$10^3$</td>
<td>22-24 hours</td>
<td>Haemorrhage throughout the embryo's body</td>
</tr>
</tbody>
</table>

Pathogenicity in SPF Chickens

Table 4. The Mean Death Time and Anatomical Pathology Appearance of The Chickens

<table>
<thead>
<tr>
<th>Sample</th>
<th>Number of Particles</th>
<th>Mean Death Time</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI C-8</td>
<td>$10^7$</td>
<td>19-22 hours</td>
<td>Haemorrhages in all organs, Cyanosis in the comb, wattles and feet</td>
</tr>
<tr>
<td>AI C-11</td>
<td>$10^7$</td>
<td>16-17 hours</td>
<td>Haemorrhages in all organs</td>
</tr>
</tbody>
</table>

Assurance of Immunogenicity of Seed Vaccine Cross Reaction Test HI

The selected isolates included the previous isolates, each of which was made into a single vaccine, namely C 8, C 10, C 11, and C 14. In addition, a single vaccine containing the AI...
clade 2.1.3 virus from the government was also made as a comparison, namely AI PWT, AI SMI, AI GARUT, and AI Clade 2.3.2 viruses, namely AI P4 (Sukoharjo), AI P6 (Sleman), while for the latest AI H5N1 Clade 2.1.3, strain A/Chicken/Barru/BBVM 41-13/2013 and the latest AI H5N1 Clade 2.3.2, strain A/Chicken/Semarang/0414225-07/2014, were tested using hyperimmune that had been made previously. All serum obtained from the results of single vaccinations and internal hyperimmune reference, then tested for HI against antigens contained in vaccines and antigens recommended by the government, including: AI PWT, AI SMI, AI P6, AI GARUT, C 5, C 6, C 8, C 10, C 14, Barru and Semarang.

**Table 5. Results of Cross Reaction of AI Vaccine Challenged with Several Antigens**

<table>
<thead>
<tr>
<th></th>
<th>PWT</th>
<th>SMI</th>
<th>GRT</th>
<th>Slm</th>
<th>C 5</th>
<th>C 6</th>
<th>C 8</th>
<th>C 10</th>
<th>C 11</th>
<th>C 13</th>
<th>C 14</th>
<th>Barru</th>
<th>Smrg</th>
</tr>
</thead>
<tbody>
<tr>
<td>PWT</td>
<td>9.5</td>
<td>3.90</td>
<td>4.70</td>
<td>4.60</td>
<td>3.30</td>
<td>3.70</td>
<td>4.60</td>
<td>1.00</td>
<td>5.65</td>
<td>1.78</td>
<td>1.40</td>
<td>1.22</td>
<td>1.03</td>
</tr>
<tr>
<td>SMI</td>
<td>7.56</td>
<td>4.30</td>
<td>5.00</td>
<td>4.10</td>
<td>3.80</td>
<td>4.00</td>
<td>6.56</td>
<td>1.90</td>
<td>4.44</td>
<td>1.80</td>
<td>2.11</td>
<td>1.65</td>
<td>2.05</td>
</tr>
<tr>
<td>GARUT</td>
<td>3.80</td>
<td>2.89</td>
<td>7.20</td>
<td>3.80</td>
<td>2.33</td>
<td>5.90</td>
<td>5.70</td>
<td>1.90</td>
<td>6.45</td>
<td>1.63</td>
<td>2.40</td>
<td>1.35</td>
<td>2.10</td>
</tr>
<tr>
<td>Sleman</td>
<td>4.00</td>
<td>2.50</td>
<td>4.00</td>
<td>7.50</td>
<td>1.75</td>
<td>3.50</td>
<td>7.00</td>
<td>1.38</td>
<td>7.22</td>
<td>3.63</td>
<td>3.90</td>
<td>2.25</td>
<td>5.50</td>
</tr>
<tr>
<td>Sukoharjo</td>
<td>3.70</td>
<td>3.00</td>
<td>5.20</td>
<td>8.10</td>
<td>2.50</td>
<td>3.30</td>
<td>6.00</td>
<td>2.00</td>
<td>6.05</td>
<td>3.60</td>
<td>3.80</td>
<td>1.50</td>
<td>5.25</td>
</tr>
<tr>
<td>C 8</td>
<td>4.00</td>
<td>2.90</td>
<td>5.10</td>
<td>5.20</td>
<td>5.60</td>
<td>4.30</td>
<td>9.10</td>
<td>3.80</td>
<td>7.65</td>
<td>2.90</td>
<td>2.90</td>
<td>4.86</td>
<td></td>
</tr>
<tr>
<td>C 10</td>
<td>2.60</td>
<td>2.50</td>
<td>3.90</td>
<td>5.11</td>
<td>2.00</td>
<td>2.90</td>
<td>4.30</td>
<td>0.40</td>
<td>6.56</td>
<td>3.33</td>
<td>3.00</td>
<td>1.25</td>
<td>2.35</td>
</tr>
<tr>
<td>C 11</td>
<td>5.30</td>
<td>4.70</td>
<td>6.60</td>
<td>7.10</td>
<td>4.40</td>
<td>5.40</td>
<td>8.30</td>
<td>6.44</td>
<td>8.55</td>
<td>4.22</td>
<td>4.20</td>
<td>5.20</td>
<td>4.50</td>
</tr>
<tr>
<td>C 14</td>
<td>3.50</td>
<td>2.90</td>
<td>4.33</td>
<td>3.00</td>
<td>2.50</td>
<td>2.90</td>
<td>5.70</td>
<td>2.22</td>
<td>4.20</td>
<td>1.10</td>
<td>2.00</td>
<td>2.15</td>
<td>3.35</td>
</tr>
<tr>
<td>Barru</td>
<td>1.50</td>
<td>2.05</td>
<td>2.53</td>
<td>3.05</td>
<td>1.30</td>
<td>2.55</td>
<td>2.50</td>
<td>1.05</td>
<td>4.35</td>
<td>2.05</td>
<td>2.01</td>
<td>7.95</td>
<td>4.20</td>
</tr>
<tr>
<td>Semarang</td>
<td>1.02</td>
<td>2.55</td>
<td>2.15</td>
<td>5.40</td>
<td>2.02</td>
<td>3.22</td>
<td>4.25</td>
<td>2.22</td>
<td>4.25</td>
<td>2.55</td>
<td>1.85</td>
<td>3.45</td>
<td>7.55</td>
</tr>
</tbody>
</table>

Note: The antibody titer in the table is the average titer log 2.

Serological results that can be said to be homologous between serum and its antigens are those with titers ≥ 25. Based on the table above, serum C 8 and C 11 derived from field isolates have a wide range of antigen binding homology compared to other sera. According to Darmawan and Wahyuningsih, 2010 in Ernawati et al. (2011), that vaccine candidates must have antigenbinding with a wide scope because it is one of the requirements for vaccine candidates. The selection of the IR test in determining vaccine seeds is one of the government regulations in accordance with the results of antisera cartography (OFFLU Workshop and AAHL 2009) where AI vaccine seeds must go through Haemagglutination Inhibition challenge tests with predetermined antisera panels (with titers ≥ 24) (Ernawati et al., 2011).

**Ensuring the Efficacy of Vaccine Finished Products**

Each vaccine candidate that has been inoculated with the AI H5N1 Clade 2.1.3 strain C-8 and C-11 based vaccine is injected into 30 chickens 4 weeks old at 1 dose/bird, after three weeks then the blood and serum are taken for serological testing using the HI method and respectively. Each batch was challenged 3 weeks after vaccination with AI H5N1 Clade 2.1.3 and AI H5N1 Clade 2.3.2 viruses with a content of 10^9ELD50/dose.

**Table 6. Efficacy of Single AI H5N1 Clade 2.1.3 strain C-8 and C-11 Vaccine Based Products**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Batch No.</th>
<th>Serology titer average (3 wpv)</th>
<th>Challenge Test (% protectifitas)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Clade 2.1 (C-8)</td>
<td>Clade 2.1 (C-11)</td>
</tr>
<tr>
<td>Group 1</td>
<td>RC09B12</td>
<td>7.40</td>
<td>6.80</td>
</tr>
<tr>
<td></td>
<td>(Single C11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 2</td>
<td>RE09B15</td>
<td>7.10</td>
<td>5.00</td>
</tr>
</tbody>
</table>
AI-based vaccines H5N1 Clade 2.1.3 strains C-8 and C-11 can stimulate the formation of antibodies at 3 weeks post-vaccination with titters greater than 2 to the power of 5 (Minimum standard titter antibody tested positive), in accordance with those stipulated in the pharmacopoeia of Indonesian Veterinary Medicine (Abdullah et al., 2023; Hartanti et al., 2023) against AI H5N1 Clade 2.1.3 or homologous to contained vaccines, however, the titter produced less than the standard against the AI H5N1 clade 2.3.2.

The protection of AI H5N1 Clade 2.1.3 strains C-8 and C-11 based vaccines products, can be seen from the results of challenge tests, where both using AI H5N1 Clade 2.1.3 challenge seeds both homologous, and heterology by using AI H5N1 Clade 2.3.2 still produces 90-100% protection, where after being challenged at 3 weeks after vaccination chickens in each treatment still survive or live without specific clinical symptoms against AI up to 14 days of observation.

**Conclusion**

Antigens derived from C 8 and C 11 vaccines can be used as vaccine seed candidates because serologically with HI assays have a wide coverage of homology against various challenging viruses, both homologous and heterology. However, this needs to be continued by conducting challenge tests followed by virus shedding tests, so that the efficacy and protnectivity of AI-based vaccines H5N1 Clade 2.1.3 strains C-8 and C-11 can be analysed by anticipating shedding or virus excretion, especially heterology which can be a risk factor for outbreaks in the field.

**Acknowledgement**

The author would like to thank the entire research and development team at veterinary vaccine plant of PT Caprifarmindo Laboratories and the management who have given permission to publish this research and development data.

**References**


